Overview

Study to Evaluate the Safety and Efficacy of Sorafenib, in Subject With Refractory Solid Tumors

Status:
Withdrawn
Trial end date:
2019-11-19
Target enrollment:
0
Participant gender:
All
Summary
This study is a single arm, pilot study of Sorafenib in patient with BRAF mutation Refractory solid tumor and specific sensitivity to Sorafenib by Avatar scan that has progressed following standard therapy or that has not responded to standard therapy or for which there is no standard therapy. To investigate the efficacy and safety of Sorafenib in patient with Refractory solid tumor.
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Samsung Medical Center
Treatments:
Niacinamide
Sorafenib
Criteria
Inclusion Criteria:

- Provision of fully informed consent prior to study specific procedures.

- Patients must be >= 19 years of age

- BRAF mutation, Refractory solid tumor and/or specific sensitivity to Sorafenib by
Avatar scan that has progressed following standard therapy or that has not responded
to standard therapy or for which there is no standard therapy.

- ECOG Performance status0-2

- Have measurable or evaluated disease based on RECIST 1.1 as determined by
investigator.

- Adequate Organ Function Laboratory values

- Absolute neutrophil count >= 1.5 x 109/L, Hemoglobin >= 9g/dL, Platelets>=100x
109/L Bilirubin <= 1.5 x upper limit of normal AST/ALT <= 2.5 X upper limit of
normal(5.0 x upper limit of normal, for subject with liver metastases)
Creatinine<= 1.5 X UNL

- Patients of child-bearing potential should be using adequate contraceptive measures
should not be breast feeding and must have a negative pregnancy test prior to start of
dosing

- Adequate heart function

Exclusion Criteria:

- Patients with second primary cancer, except:adequately treated non-melanoma skin
cancer, curatively treated in-situ cancer of the cervix, or other solid tumor
curatively treated with no evidence of disease for <= 5 years.

- Has known active central nervous system(CNS) metastases

- Has an active infection requiring systemic therapy

- Pregnancy or breast feeding

- Patients with cardiac problem

- Any previous treatment with Sorafenib